In our patient, ruxolitinib produced virtually no clinical or hematologic benefit, consistent with the marked heterogeneity in JAK-inhibitor sensitivity reported in PCM1::JAK2-rearranged neoplasms. The gene discussed is JAK2; the disease is neoplasm.